Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(31 sites)
United States
University of California-Irvine Medical Center, Irvine, California Cedars-Sinai Medical Center, Los Angeles, California University of California, Los Angeles (UCLA) Medical Center, Los Angeles, California Scripps Clinic, San Diego, California Colorado Blood Cancer Institute, Denver, Colorado